AmplifyBio, a Contract Development and Manufacturing Organization and Contract Research Organization, and RNAV8 Bio, a rising startup specializing in mRNA engineering platforms,

Arrivo Bio has announced a significant advancement in the fight against major depressive disorder by initiating dosing for the first patient in the SP-624-202 clinical trial.

Walden Biosciences, Inc., a privately funded clinical development company specializing in innovative therapies for kidney diseases, has announced the results from its Phase 1+ clinical trial of WAL0921 in healthy individuals. WAL0921 represents Walden's novel

ORIC Pharmaceuticals, Inc. has completed the dose escalation phase of the Phase 1b trial for ORIC-114, a treatment targeting advanced solid tumors with EGFR and HER2 exon 20 alterations or HER2 amplifications

Oncocyte Corporation, a company specializing in precision diagnostics, has announced a partnership with Bio-Rad Laboratories, a prominent player in life science research and clinical diagnostics.

Ocugen, Inc., a biotechnology company specializing in gene and cell therapies, and vaccines, has announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency

Lonza and NeuroSense Therapeutics Ltd. have formed a collaboration to investigate biological changes occurring in individuals with neurodegenerative diseases, including ALS. NeuroSense will have access to Lonza's advanced expertise and capabilities

Corvus Pharmaceuticals, Inc. has initiated a Phase 1 clinical trial to evaluate soquelitinib in patients with moderate to severe atopic dermatitis. This trial, which is randomized, double-blind, and placebo-controlled,

Ocugen, Inc., a biotechnology firm specializing in the discovery, development, and commercialization of innovative gene and cell therapies, along with vaccines, has announced the approval of its Investigational New Drug

Dizal announced today that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to its drug sunvozertinib as the primary treatment for patients